Abstract
Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.
| Original language | English |
|---|---|
| Pages (from-to) | 162-177 |
| Number of pages | 16 |
| Journal | JNCI Monographs |
| Volume | 41 |
| DOIs | |
| Publication status | Published - 1 Jan 2010 |
Fingerprint
Keywords
- breast cancer
- oncology
- clinical trials
- radiotherapy
Cite this
}
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. / Godwin, Jon.
In: JNCI Monographs, Vol. 41, 01.01.2010, p. 162-177.Research output: Contribution to journal › Article
TY - JOUR
T1 - Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
AU - Godwin, Jon
N1 - <p>Originally published in: JNCI Monographs (2010), 41, pp.162-177.</p>
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.
AB - Individual patient data were available for all four of the randomized trials that began before 1995, and that compared adjuvant radiotherapy vs no radiotherapy following breast-conserving surgery for ductal carcinoma in situ (DCIS). A total of 3729 women were eligible for analysis. Radiotherapy reduced the absolute 10-year risk of any ipsilateral breast event (ie, either recurrent DCIS or invasive cancer) by 15.2% (SE 1.6%, 12.9% vs 28.1% 2 P <.00001), and it was effective regardless of the age at diagnosis, extent of breast-conserving surgery, use of tamoxifen, method of DCIS detection, margin status, focality, grade, comedonecrosis, architecture, or tumor size. Jon Godwin is a member of the EBCTCG, which is the group author for this article.
KW - breast cancer
KW - oncology
KW - clinical trials
KW - radiotherapy
U2 - 10.1093/jncimonographs/lgq039
DO - 10.1093/jncimonographs/lgq039
M3 - Article
VL - 41
SP - 162
EP - 177
JO - JNCI Monographs
JF - JNCI Monographs
SN - 1052-6773
ER -